Zaxis International Inc. Elects New Board of Directors
HUDSON, Ohio--(BUSINESS WIRE)--Jan. 5, 2000 -- Zaxis International Inc. (OTC BB:ZAXS - news) announced today the election of a new slate of directors to its board, effective in December 1999.
Ronald Hanson was elected chairman of the board. Hanson is founder of his own financial planning firm and is a Chartered Financial Consultant with nearly 40 years of professional experience working with high net worth business owners and executives. He has served as a director and trustee on a number of corporate and civic boards in the Cleveland area. Hanson has been an investor in Zaxis International since 1991.
Malvin Eutick is a non-executive director of a number of biotechnology and medical start up companies in Australia including Progen Industries Pty Ltd. and TUTA Laboratories Pty Ltd. Dr. Eutick is executive director of Ophthalmic Laboratories Pty Ltd., an Australian based pharmaceutical company. In 1995 Dr. Eutick was awarded the medal of the Order of Australia for his services to the field of Australian biotechnology, especially for his work in assisting start up ventures to the commercialization stages of their technology.
Steven Ficyk is a registered investment professional. Over the past 17 years, he has held positions with Merrill Lynch and A.G. Edwards, serving both retail and institutional investors. Ficyk is currently associated with Round Hill Securities Inc. in Brunswick, Ohio.
Stephen N. Anderson is president of Six Sigma Group Inc., a San Francisco based strategic management consulting firm focused on pre-public and public growth companies in the United States and offshore. Anderson is an advisor to senior management and the board of directors of several public and privately owned companies.
Melvin Weisblatt is currently the vice president of sales and marketing for Zaxis International, a position he has held since 1996. Prior to joining Zaxis International, he held senior management positions with Amersham Inc. and United States Biochemical Corp.
``The election of these new Board members provides a solid foundation for Zaxis International Inc. as we move into the growth phase of our business,'' said John Hrobsky, president and chief executive officer. ``Their considerable experience with new and emerging companies and their extensive knowledge of the financial and biotechnology industries is particularly valuable to the management teams of the Company.'' Hrobsky added, ``Their addition to our Board of Directors continues our plan to strengthen the Company's position as a leading provider of electrophoresis gels for blood protein and DNA testing to the research and clinical markets.''
Zaxis International Inc. is a biotechnology company that produces electrophoresis gels for testing blood proteins and various genetic compounds. Zaxis produces these gels for the research and clinical markets. The company is a leader in this high growth market and is poised to take advantage of its leading edge technology.
Statements in this press release that relate to matters that are not historic fact are forward-looking statements that involve market risks and uncertainties including, but not limited to, the ability of Zaxis International to develop and commercialize the products that are subject to this program and other risks and uncertainties in the company's Securities and Exchange filings.